Browse HDAC11

Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Note=Predominantly nuclear.
Domain PF00850 Histone deacetylase domain
Function

Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes.

> Gene Ontology
 
Biological Process GO:0006476 protein deacetylation
GO:0010001 glial cell differentiation
GO:0014003 oligodendrocyte development
GO:0016570 histone modification
GO:0016575 histone deacetylation
GO:0021782 glial cell development
GO:0035601 protein deacylation
GO:0042063 gliogenesis
GO:0048709 oligodendrocyte differentiation
GO:0070932 histone H3 deacetylation
GO:0098732 macromolecule deacylation
Molecular Function GO:0004407 histone deacetylase activity
GO:0008134 transcription factor binding
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0017136 NAD-dependent histone deacetylase activity
GO:0019213 deacetylase activity
GO:0031078 histone deacetylase activity (H3-K14 specific)
GO:0032041 NAD-dependent histone deacetylase activity (H3-K14 specific)
GO:0033558 protein deacetylase activity
GO:0034979 NAD-dependent protein deacetylase activity
Cellular Component GO:0000118 histone deacetylase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HDAC11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HDAC11 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21239696Hodgkin LymphomaInhibit immunity (T cell function)The engagement of OX40L with the OX40 receptor is essential for the generation of antigen-specific memory T cells and for the induction of host antitumor immunity. Small interfering RNAs (siRNAs) that selectively inhibited HDAC11 expression, significantly up-regulated OX40L and induced apoptosis in HL cell lines, and silencing HDAC11 transcripts increased the production of tumor necrosis-α (TNF-α) and IL-17 in the supernatants of HL cells. Furthermore, HDACI-induced OX40L inhibited the generation of IL-10-producing type 1 T-reg cells. These results demonstrate for the first time that HDAC11 plays an essential role in regulating OX40L expression.
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HDAC11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HDAC11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3350.365
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1310.923
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4810.654
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1780.772
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3440.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.840.622
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.060.863
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2440.823
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1960.877
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1970.871
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0760.965
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.170.113
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HDAC11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HDAC11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HDAC11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HDAC11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HDAC11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HDAC11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HDAC11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHDAC11
Namehistone deacetylase 11
Aliases HD11
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HDAC11 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HDAC11.
ID Name Drug Type Targets #Targets
DB05015BelinostatSmall MoleculeHDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, H ......11
DB06603PanobinostatSmall MoleculeHDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, H ......11